Table 3.
Disease characteristics in RA patients according to ROS production and NO synthesis.
| ROS | NO | |||||
|---|---|---|---|---|---|---|
| Normal (n = 15) | High (n = 57) | P | Normal (n = 22) | Low (n = 50) | P | |
| Disease duration (years) | 15.2 (±11.2) | 14.0 (±9.3) | 0.674 | 15.3 (±7.9) | 14.2 (±10.4) | 0.644 |
| Prednisolone dose (mg/day) | 8.7 (±2.3) | 8.2 (±2.9) | 0.553 | 9.0 (±2.8) | 8.0 (±2.7) | 0.176 |
| Tender joints | 2.3 (±3.8) | 3.2 (±4.0) | 0.436 | 3.2 (±3.5) | 3.0 (±4.1) | 0.748 |
| Swollen joints | 2.6 (±3.0) | 2.7 (±3.6) | 0.938 | 3.0 (±3.1) | 2.5 (±3.6) | 0.598 |
| Global assessment (mm) | 36.7 (±24.1) | 49.1 (±23.7) | 0.076 | 43.2 (±24.2) | 47.6 (±24.0) | 0.482 |
| VAS (mm) | 42.7 (±24.0) | 54.8 (±24.6) | 0.091 | 56.0 (±28.1) | 50.9 (±23.3) | 0.435 |
| DAS28 | 3.4 (±1.1) | 3.8 (±1.2) | 0.248 | 4.0. (±1.0) | 3.6 (±1.2) | 0.123 |
| HAQ | 1.0 (±0.9) | 1.2 (±0.9) | 0.209 | 1.4 (±1.0) | 1.3 (±0.9) | 0.775 |
| ESR (mm/h) | 20.6 (±10.2) | 22.7 (±16.7) | 0.548 | 24.0 (±12.7) | 20.8 (±16.7) | 0.420 |
| Anti-CCP (UA/mL) | 37.0 (±83.9) | 52.6 (±93.1) | 0.570 | 72.6 (±95.4) | 38.8 (±87.1) | 0.152 |
| RF (mg/dL) | 90.1 (±132.6) | 282.8 (±493.2) | 0.012 * | 325.0 (±690.7) | 203.8 (±288.6) | 0.436 |
Results are expressed as mean ± SD. VAS, visual analogue scale; DAS28, disease activity score in 28 joints; HAQ, Health Assessment Questionnaire; ESR, erythrocyte sedimentation rate; anti-CCP, anti-cyclic citrullinated peptide; RF, rheumatoid factor. * P < 0.05 was considered significant.